Transcutaneous Electrical Acustimulation Improved the Quality of Life in Patients With Diarrhea-Irritable Bowel Syndrome

Neuromodulation. 2022 Dec;25(8):1165-1172. doi: 10.1016/j.neurom.2021.10.009. Epub 2021 Dec 18.

Abstract

Background and aim: Patients with diarrhea-dominant irritable bowel syndrome (IBS-D) experience abdominal pain and reduced quality of life and need effective treatments. This study aimed to evaluate whether transcutaneous electrical acustimulation (TEA) at two acupuncture points, LI4 and ST36, could improve pain and quality of life of patients with IBS-D.

Materials and methods: A total of 42 patients with IBS-D who met the Rome IV criteria were randomly divided into two groups: TEA and sham-TEA. TEA was performed through acupoints Hegu (LI4) and Zusanli (ST36) for one hour twice daily for one month, using previously established parameters; sham-TEA was delivered in the same way as TEA but without actual electrical current stimulation.

Results: The sham-TEA group showed a significantly higher rate of drop-out than the TEA group (29% vs 0%, p = 0.021). TEA, but not sham-TEA, significantly improved quality of life (before: 78.55 ± 9.62, after: 85.97 ± 9.49, p < 0.0001). Both TEA and sham-TEA reduced abdominal pain; however, TEA was more potent than sham-TEA (p = 0.014). The IBS symptom severity scale score was reduced by both TEA and sham-TEA. Autonomic functions assessed by plasma norepinephrine and pancreatic polypeptide were not altered with TEA, nor was interleukin 10 or interleukin 6.

Conclusions: TEA at LI4 and ST36 improves abdominal pain and quality of life of patients with IBS-D, probably mediated by mechanisms other than autonomic function or inflammatory cytokines.

Keywords: Abdominal pain; diarrhea-irritable bowel syndrome; quality of life; transcutaneous electrical stimulation.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Abdominal Pain / etiology
  • Abdominal Pain / therapy
  • Acupuncture Therapy*
  • Diarrhea / etiology
  • Diarrhea / therapy
  • Humans
  • Irritable Bowel Syndrome* / therapy
  • Quality of Life